Previously, CD36 ligands of the growth hormone-releasing peptide family (e.g., GHRP-6) have been shown to reduce atherosclerosis progression, dampen mononuclear cell recruitment to lesion areas, increase cellular cholesterol efflux, and reverse cholesterol transport (Marleau et al., 2005; Bujold et al., 2009; Harb et al., 2009; Bujold et al., 2013). Here, CD36 is linked to atherosclerosis.